Secukinumab, a engineered immunoglobulin , represents a crucial advance in the approach of inflammatory disorders. Its main mechanism of action involves specifically neutralizing this inflammatory cytokine, a cytokine associated in the progression of conditions like psoriatic inflammation and scaling skin . By suppressing the this signaling pathway

Basiliximab, previously identified as CHI 621 and possessing the molecular identifier 179045-86-4, represents a therapeutic agent utilized primarily in suppressing acute repudiation following organ transplantation . This modified protein specifically interacts with the interleukin-2 (IL-2) sensor , effectively inhibiting IL-2 communication and subs